Five-year clinical efficacy and safety of contemporary thin-strut biodegradable polymer versus durable polymer drug-eluting stents: a systematic review and meta-analysis of 9 randomized controlled trials-Reference-Cited by-同舟云学术

Five-year clinical efficacy and safety of contemporary thin-strut biodegradable polymer versus durable polymer drug-eluting stents: a systematic review and meta-analysis of 9 randomized controlled trials

Published:2019-08-17 Issue:3 Volume:35 Page:250-258
ISSN:1868-4300
Container-title:Cardiovascular Intervention and Therapeutics
language:en
Short-container-title:Cardiovasc Interv and Ther

Author:

Kobayashi Tomoaki,Sotomi Yohei,Suzuki Satoshi,Suwannasom Pannipa,Nakatani Shimpei,Morino Yoshihiro,Ako Junya,Kozuma Ken,Hirayama Atsushi,Sakata Yasushi,Higuchi Yoshiharu

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12928-019-00613-w.pdf

Reference40 articles.

1. Otsuka F, Vorpahl M, Nakano M, Foerst J, Newell JB, Sakakura K, Kutys R, Ladich E, Finn AV, Kolodgie FD, et al. Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans. Circulation. 2014;129(2):211–23.

2. Naidu SS, Krucoff MW, Rutledge DR, Mao VW, Zhao W, Zheng Q, Wilburn O, Sudhir K, Simonton C, Hermiller JB, et al. Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study. JACC Cardiovasc Interv. 2012;5(6):626–35.

3. Lu P, Lu S, Li Y, Deng M, Wang Z, Mao X. A comparison of the main outcomes from BP-BES and DP-DES at five years of follow-up: a systematic review and meta-analysis. Sci Rep. 2017;7(1):14997.

4. Räber L, Magro M, Stefanini GG, Kalesan B, van Domburg RT, Onuma Y, Wenaweser P, Daemen J, Meier B, Jüni P, et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents. Circulation. 2012;125(9):1110–21.

5. Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabaté M, Smits PC, Kaiser C, D’Ascenzo F, Frati G, Mancone M, et al. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents. J Am College Cardiol. 2014;63(4):299–307.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug-eluting stents for coronary artery disease in the perspective of bibliometric analysis;Frontiers in Cardiovascular Medicine;2024-02-19

2. The Newer-Generation DES, Really Nothing to Special?;Korean Circulation Journal;2024

3. Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable-polymer coronary stent – five-year results of the TARGET All Comers randomised clinical trial;EuroIntervention;2023-12

4. Long-term outcomes of renal denervation in the treatment of comorbid patients with hypertension, diabetes and coronary atherosclerosis;Cardiovascular Therapy and Prevention;2023-10-06

5. Contemporary coronary drug-eluting and coated stents: an updated mini-review (2023);Cardiovascular Intervention and Therapeutics;2023-09-01